These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 14636164)
1. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Rousseau E; Ruchoux MM; Scaravilli F; Chapon F; Vinchon M; De Smet C; Godfraind C; Vikkula M Neuropathol Appl Neurobiol; 2003 Dec; 29(6):574-83. PubMed ID: 14636164 [TBL] [Abstract][Full Text] [Related]
2. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes. Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049 [TBL] [Abstract][Full Text] [Related]
3. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. Wolter M; Reifenberger J; Blaschke B; Ichimura K; Schmidt EE; Collins VP; Reifenberger G J Neuropathol Exp Neurol; 2001 Dec; 60(12):1170-80. PubMed ID: 11764089 [TBL] [Abstract][Full Text] [Related]
4. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924 [TBL] [Abstract][Full Text] [Related]
5. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910 [TBL] [Abstract][Full Text] [Related]
6. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation. Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918 [TBL] [Abstract][Full Text] [Related]
7. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Lindsey JC; Lusher ME; Anderton JA; Bailey S; Gilbertson RJ; Pearson AD; Ellison DW; Clifford SC Carcinogenesis; 2004 May; 25(5):661-8. PubMed ID: 14688019 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Endo M; Kobayashi C; Setsu N; Takahashi Y; Kohashi K; Yamamoto H; Tamiya S; Matsuda S; Iwamoto Y; Tsuneyoshi M; Oda Y Clin Cancer Res; 2011 Jun; 17(11):3771-82. PubMed ID: 21262917 [TBL] [Abstract][Full Text] [Related]
9. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Laharanne E; Chevret E; Idrissi Y; Gentil C; Longy M; Ferrer J; Dubus P; Jouary T; Vergier B; Beylot-Barry M; Merlio JP Mod Pathol; 2010 Apr; 23(4):547-58. PubMed ID: 20118908 [TBL] [Abstract][Full Text] [Related]
10. Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status. Chaussade L; Eymin B; Brambilla E; Gazzeri S Oncogene; 2001 Oct; 20(45):6587-96. PubMed ID: 11641784 [TBL] [Abstract][Full Text] [Related]
11. Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human atherosclerotic plaque. Holdt LM; Sass K; Gäbel G; Bergert H; Thiery J; Teupser D Atherosclerosis; 2011 Feb; 214(2):264-70. PubMed ID: 20637465 [TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Furonaka O; Takeshima Y; Awaya H; Ishida H; Kohno N; Inai K Pathol Int; 2004 Aug; 54(8):549-55. PubMed ID: 15260845 [TBL] [Abstract][Full Text] [Related]
13. [Abnormal methylation of several tumor suppressor genes in sporadic breast cancer]. Zemliakova VV; Zhevlova AI; Strel'nikov VV; Liubchenko LN; Vishnevskaia IaV; Tret'iakova VA; Zaletaev DV; Nemtsova MV Mol Biol (Mosk); 2003; 37(4):696-703. PubMed ID: 12942643 [TBL] [Abstract][Full Text] [Related]
14. Alterations of p14 López F; Sampedro T; Llorente JL; Hermsen M; Álvarez-Marcos C Pathol Oncol Res; 2017 Jan; 23(1):63-71. PubMed ID: 27377733 [TBL] [Abstract][Full Text] [Related]
15. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113 [TBL] [Abstract][Full Text] [Related]
16. Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma. Chinnasri P; Pairojkul C; Jearanaikoon P; Sripa B; Bhudhisawasdi V; Tantimavanich S; Limpaiboon T Hum Pathol; 2009 Jun; 40(6):817-26. PubMed ID: 19200577 [TBL] [Abstract][Full Text] [Related]
17. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362 [TBL] [Abstract][Full Text] [Related]
18. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835 [TBL] [Abstract][Full Text] [Related]
19. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis. Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779 [TBL] [Abstract][Full Text] [Related]
20. Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas. Simon M; Köster G; Menon AG; Schramm J Acta Neuropathol; 1999 Nov; 98(5):444-52. PubMed ID: 10541865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]